Cartesian Therapeutics, Inc. (RNAC) Q1 2024 Earnings
RNAC·Reported May 8, 2024·Before market open
Cartesian Therapeutics, Inc. reported Q1 2024 revenue of $5.8M, beat analyst consensus of $1.7M by $4.2M. Diluted EPS came in at $-1.97, missed the $-0.81 consensus by $1.16.
Revenue
$5.8Mbeat by $4.2M
Consensus: $1.7MDiluted EPS
$-1.97missed by $1.16
Consensus: $-0.81
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Cartesian Therapeutics, Inc.'s Q1 2024 earnings report.
Cartesian Therapeutics, Inc. (RNAC) reported Q1 2024 earnings on May 8, 2024 before market open.
Cartesian Therapeutics, Inc. reported revenue of $5.8M and diluted EPS of $-1.97 for Q1 2024.
Revenue beat the consensus estimate of $1.7M by $4.2M. EPS missed the consensus estimate of $-0.81 by $1.16.
You can read the 10-Q periodic report (0001453687-24-000082) directly on SEC EDGAR. The filing index links above go to sec.gov.